TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 19:02 · Cybersecurity · Content Credentials initiative builds digital provenance infrastructure against deepfakes
episode briefing
In Good Company with Nicolai Tangen

Shantanu Narayen - CEO of Adobe | Podcast | In Good Company | Norges Bank Investment Management

2024-06-05 · 3 company · 5 thematic
sentiment
3 bull0 bear0 neu
speakers
shantanu narayen

Shantanu Narayen has been CEO of Adobe since 2007 and Chair since 2019. He led Adobe's transition to cloud subscription model, built the $5B+ Experience Cloud digital marketing business, and serves on the board of Pfizer. He grew up in Hyderabad, India, and holds an MBA from UC Berkeley.

now playing · Cybersecurity
AI Infrastructuretailwindscore 9/10shantanu narayen
Generative AI is a massive tailwind expanding creative software TAM
Narayen argues every major technology shift (cloud, mobile, AI) expands Adobe's addressable market; generative AI eliminates the 'blank page' problem, automates mundane tasks, and enables c…
Cybersecuritytailwindscore 8/10shantanu narayen
Content Credentials initiative builds digital provenance infrastructure against deepfakes
Adobe leads the Content Authenticity Initiative with thousands of partners (camera makers, Meta, NYT, BBC) embedding cryptographic provenance metadata from capture through edit to distribut…
Enterprise Softwaretailwindscore 7/10shantanu narayen
Experience Cloud built from scratch into $5B+ digital experience platform
Adobe identified unmet need for marketing automation when moving to direct customer engagement, acquired Omniture and Day Software, built real-time CDP organically, and now uses AI to deliv…
AI Geopolitics & Export Controlstailwindscore 7/10shantanu narayen
India's tech ecosystem maturing with reverse talent migration and global ambitions
Narayen observes Indian entrepreneurs now have global aspirations with access to capital and talent locally, reversing the historical brain drain to the US. He warns against post-COVID prot…
Private Marketsriskscore 6/10shantanu narayen
Long-horizon medicinal bets require investor patience beyond typical fund cycles
From Pfizer board experience, Narayen notes pharmaceutical moonshots like COVID vaccines have such long development timelines that successors often reap the rewards, illustrating a structur…